Arietis focuses on antimicrobial discovery and therapies for recalcitrant infections. Current antibiotics work in conjunction with the immune system and are unable to completely eradicate the pathogen. Survival is due to microbial cells entering into a dormant state, which is tolerant to antimicrobials. These tolerant cells can be responsible for chronic and relapsing infections.
Our goal is to develop sterilizing antibiotics for the following indications:
- Skin and soft tissue infections with S. aureus and MRSA
- Gastritis due to Helicobacter pylori
- Bacterial and fungal infection of implanted medical devices
Pathogenic bacteria continually develop and spread resistance, yet the antibacterial armamentarium is increasingly limited. Founded in 2008, Arietis bridges an important gap in antimicrobial drug discovery and technology development. Arietis has forged productive alliances and partnerships within the biotechnology community as we advance our capacity to develop effective drug products. We are committed to building value for our partners and shareholders, and are well positioned to capitalize on the growing antimicrobial market. We are committed to providing innovative solutions for the problem of persistent infections, thereby decreasing the overall burden on healthcare worldwide.